BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Immunai Inc.

Headquarters: New York, NY, United States of America
Year Founded: 2018
Status: Private

BioCentury | Mar 7, 2025
Management Tracks

Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus

Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
BioCentury | Apr 18, 2024
Management Tracks

Protego names Warner CEO

Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Oct 28, 2021
Deals

Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215M

Plus Teva and Modag partner, Fosun, Novavax and DBV
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for Versant-grown
Items per page:
1 - 4 of 4